This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Thomas W. Wilson, MD; Helen S. L. Chan, MB, BS; Galina M. Moselhy, MSc; Duane D. Heydt, Jr, MSPH; Carolin M. Frey, PhD; Brenda L. Gallie, MD

Arch Ophthalmol. 1996;114(11):1390-1395.

Abstract
Objective
To investigate whether cryotherapy, which induces a serous effusion in retina, might increase access of systemic chemotherapy into the vitreous.

Methods
The right eyes of 18 rabbits were treated with triple or single freeze-thaw cryotherapy at 1 or 2 locations, 1 day before administering intravenous carboplatin with or without cyclosporine. Control left eyes received no cryotherapy. The rabbits were killed 2 or 24 hours after chemotherapy, and carboplatin concentrations were measured in the vitreous of each eye and in blood.

Results
A significant increase was found in intravit-real carboplatin concentrations when cryotherapy was applied (P<.001) or high-dose cyclosporine was administered (P<.001) and if 2 locations were frozen compared with 1 location frozen (P=.02). Intravitreal carboplatin concentrations were always significantly greater after cryotherapy, either when the corresponding blood carboplatin concentrations were high (2 hours after completing treatment) or when they had dropped to much lower levels (at 24 hours). The triple freeze-thaw technique did not yield significantly better results than a single freeze-thaw technique.

Conclusion
Cryotherapy administered 24 hours before chemotherapy significantly increased the intravit-real penetration of carboplatin, and this strategy may enhance the capacity of chemotherapy to cure intraocular retinoblastoma, particularly avascular tumors such as vitreous seeds.

Author Affiliations
From the Department of Pediatric Ophthalmology (Dr Wilson) and the Janet Weis Research Center (Mr Heydt and Dr Frey), Geisinger Medical Center, University of Pennsylvania, Danville; the Divisions of Hematology/Oncology (Dr Chan) and Immunology and Cancer Research (Drs Gallie and Chan), The Hospital for Sick Children Research Institute, and the Departments of Ophthalmology, Molecular and Medical Genetics (Dr Gallie), and Pediatrics (Dr Chan), The Hospital for Sick Children and the University of Toronto; and Occupational Health Laboratory, Ontario Ministry of Labour (Ms Moselhy); Toronto, Ontario. None of the authors has proprietary interest in the development or marketing of the agents that were used in the study.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

A Phase I Study of Periocular Topotecan in Children with Intraocular Retinoblastoma
Chantada et al.
IOVS 2009;50:1492-1496.
ABSTRACT | FULL TEXT  

Eye-Preservation Treatment of Retinoblastoma with Vitreous Seeding
Kaneko and Suzuki
Jpn J Clin Oncol 2003;33:601-607.
ABSTRACT | FULL TEXT  

Treatment of Intraocular Retinoblastoma With Vincristine and Carboplatin
Rodriguez-Galindo et al.
JCO 2003;21:2019-2025.
ABSTRACT | FULL TEXT  

Factors Predictive of Recurrence of Retinal Tumors, Vitreous Seeds, and Subretinal Seeds Following Chemoreduction for Retinoblastoma
Shields et al.
Arch Ophthalmol 2002;120:460-464.
ABSTRACT | FULL TEXT  

First-Line Chemotherapy With Local Treatment Can Prevent External-Beam Irradiation and Enucleation in Low-Stage Intraocular Retinoblastoma
Beck et al.
JCO 2000;18:2881-2887.
ABSTRACT | FULL TEXT  

Intraocular Concentrations of Chemotherapeutic Agents After Systemic or Local Administration
Mendelsohn et al.
Arch Ophthalmol 1998;116:1209-1212.
ABSTRACT | FULL TEXT  

Subconjunctival Carboplatin Therapy and Cryotherapy in the Treatment of Transgenic Murine Retinoblastoma
Murray et al.
Arch Ophthalmol 1997;115:1286-1290.
ABSTRACT